Psychobiotic PS128 consumption shows benefits to Parkinson s symptoms in new clinical study
News provided by
Share this article
Share this article
TAIPEI, Feb. 18, 2021 /PRNewswire/ Bened Biomedical, a leading Taiwanese probiotic company, has announced a successful clinical study for its PS128 psychobiotic in treating symptoms of Parkinson s disease (PD). The study was led by a neurologist, Dr. Chin-Song Lu, a renowned researcher for PD in Taiwan.
R&D team of Bened Biomedical
Psychobiotics are probiotics which yield specific mental health benefits. PS128, a strain of
Lactobacillus plantarum, is able to modulate dopamine and serotonin neurotransmitter levels. When these levels are abnormal, conditions such as autism spectrum disorder (ASD), depression, and PD can arise. In separate prior studies, PS128 has been shown to be effective against autism and depression.
Patented psychobiotic Lactobacillus plantarum PS128™ is now Self-affirmed GRAS
Share Article
Bened Biomedical Co. Ltd., a global leader of functional probiotics esp. psycho-biotics and REJMIUS, INC. proudly announce the newest Self-affirmed GRAS status of the patented psychobiotic Lactobacillus plantarum PS128™ for the immediate sales and distribution in the United States. TAIPEI, Taiwan (PRWEB) December 22, 2020 Bened Biomedical Co. Ltd., a global leader of functional probiotics esp. psycho-biotics and REJIMUS, INC. proudly announce the newest Self-affirmed GRAS status of the patented psychobiotic Lactobacillus plantarum PS128™ for the immediate sales and distribution in the United States.
“Our commitment and employing a clinical development strategy for novel ingredients such as PS128™ is really leading the way to create evidence-based functional food and supplement products in the marketplace overal